81 related articles for article (PubMed ID: 20501625)
1. A phase I study of 5-fluorouracil/leucovorin and arsenic trioxide for patients with refractory/relapsed colorectal carcinoma.
Ardalan B; Subbarayan PR; Ramos Y; Gonzalez M; Fernandez A; Mezentsev D; Reis I; Duncan R; Podolsky L; Lee K; Lima M; Ganjei-Azar P
Clin Cancer Res; 2010 Jun; 16(11):3019-27. PubMed ID: 20501625
[TBL] [Abstract][Full Text] [Related]
2. Safety and antitumor activity of arsenic trioxide plus infusional 5-fluorouracil, leucovorin, and irinotecan as second-line chemotherapy for refractory metastatic colorectal cancer: A pilot study from South India.
Lakshmaiah KC; Chaudhuri T; Babu GK; Lokanatha D; Jacob LA; Suresh Babu MC; Rudresha AH; Lokesh KN; Rajeev LK
Indian J Cancer; 2017; 54(4):631-633. PubMed ID: 30082548
[TBL] [Abstract][Full Text] [Related]
3. A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy.
Wilson PM; El-Khoueiry A; Iqbal S; Fazzone W; LaBonte MJ; Groshen S; Yang D; Danenberg KD; Cole S; Kornacki M; Ladner RD; Lenz HJ
Cancer Chemother Pharmacol; 2010 Apr; 65(5):979-88. PubMed ID: 20062993
[TBL] [Abstract][Full Text] [Related]
4. Arsenic trioxide suppresses thymidylate synthase in 5-FU-resistant colorectal cancer cell line HT29 In Vitro re-sensitizing cells to 5-FU.
Subbarayan PR; Lee K; Ardalan B
Anticancer Res; 2010 Apr; 30(4):1157-62. PubMed ID: 20530422
[TBL] [Abstract][Full Text] [Related]
5. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
[TBL] [Abstract][Full Text] [Related]
6. [Chronotherapy with high dose carboplatin, 5-fluorouracil and leucovorin in advanced colorectal carcinoma].
Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević A
Srp Arh Celok Lek; 1998; 126(9-10):355-61. PubMed ID: 9863407
[TBL] [Abstract][Full Text] [Related]
7. 5-Fluorouracil/Leucovorin and arsenic trioxide for patients with refractory/relapsed colorectal carcinoma: a clinical experience.
Podolsky L; Oh M; Subbarayan PR; Francheschi D; Livingstone A; Ardalan B
Acta Oncol; 2011 May; 50(4):602-5. PubMed ID: 20950119
[No Abstract] [Full Text] [Related]
8. Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer.
Chau I; Webb A; Cunningham D; Hill M; Waters JS; Norman A; Massey A
Br J Cancer; 2001 Nov; 85(9):1258-64. PubMed ID: 11720458
[TBL] [Abstract][Full Text] [Related]
9. Bimonthly high dose leucovorin and 5-fluorouracil 48-hour continuous infusion in patients with advanced colorectal carcinoma. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD).
Beerblock K; Rinaldi Y; André T; Louvet C; Raymond E; Tournigand C; Carola E; Favre R; de Gramont A; Krulik M
Cancer; 1997 Mar; 79(6):1100-5. PubMed ID: 9070486
[TBL] [Abstract][Full Text] [Related]
10. Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study.
Taïeb J; Artru P; Paye F; Louvet C; Perez N; André T; Gayet B; Hebbar M; Goebel FM; Tournigand C; Parc R; de Gramont A
J Clin Oncol; 2005 Jan; 23(3):502-9. PubMed ID: 15659495
[TBL] [Abstract][Full Text] [Related]
11. Activity of high dose 24 hour 5-fluorouracil infusion plus L-leucovorin in advanced colorectal cancer.
Nobile MT; Barzacch MC; Sanguineti O; Chiara S; Gozza A; Vincenti M; Lavarello A; Cognein P; Lionetto R; Percivale PL; Bertoglio S; Murolo C; Esposito M; Vannozzi MO; Rosso R
Anticancer Res; 1998; 18(1B):517-21. PubMed ID: 9568171
[TBL] [Abstract][Full Text] [Related]
12. Phase I/II study of oxaliplatin with weekly bolus fluorouracil and high-dose leucovorin (ROX) as first-line therapy for patients with colorectal cancer.
Yamada Y; Ohtsu A; Boku N; Miyata Y; Shimada Y; Doi T; Muro K; Muto M; Hamaguchi T; Mera K; Yano T; Tanigawara Y; Shirao K
Jpn J Clin Oncol; 2006 Apr; 36(4):218-23. PubMed ID: 16684860
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
[TBL] [Abstract][Full Text] [Related]
14. Advanced colorectal carcinoma. A prospective randomized trial of sequential methotrexate, 5-fluorouracil, and leucovorin versus 5-fluorouracil alone.
Machiavelli M; Leone BA; Romero A; Rabinovich MG; Vallejo CT; Bianco A; Pérez JE; Rodríguez R; Cuevas MA; Alvarez LA
Am J Clin Oncol; 1991 Jun; 14(3):211-7. PubMed ID: 2031508
[TBL] [Abstract][Full Text] [Related]
15. Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil.
Aschele C; Debernardis D; Bandelloni R; Cascinu S; Catalano V; Giordani P; Barni S; Turci D; Drudi G; Lonardi S; Gallo L; Maley F; Monfardini S
Ann Oncol; 2002 Dec; 13(12):1882-92. PubMed ID: 12453856
[TBL] [Abstract][Full Text] [Related]
16. A phase II and pharmacologic study of fluorouracil given by a 1-hour infusion daily for 5 days with leucovorin and interferon alpha-2a in adenocarcinoma of the large bowel.
Ismail AS; Quinn MG; Wright MA; Ernst A; Kao V; Grogan L; Parr A; Grollman F; Kirsch IR; Grem JL
Oncol Rep; 2005 Jun; 13(6):1145-52. PubMed ID: 15870935
[TBL] [Abstract][Full Text] [Related]
17. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin.
Leichman CG; Lenz HJ; Leichman L; Danenberg K; Baranda J; Groshen S; Boswell W; Metzger R; Tan M; Danenberg PV
J Clin Oncol; 1997 Oct; 15(10):3223-9. PubMed ID: 9336359
[TBL] [Abstract][Full Text] [Related]
18. A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors.
Fakih MG; Fetterly G; Egorin MJ; Muindi JR; Espinoza-Delgado I; Zwiebel JA; Litwin A; Holleran JL; Wang K; Diasio RB
Clin Cancer Res; 2010 Jul; 16(14):3786-94. PubMed ID: 20463088
[TBL] [Abstract][Full Text] [Related]
19. A combination of thalidomide and arsenic trioxide is effective and well tolerated in patients with myelodysplastic syndromes.
Wei W; Zhou F; Zhang Y; Guo L; Shi H; Hou J
Leuk Res; 2012 Jun; 36(6):715-9. PubMed ID: 22277680
[TBL] [Abstract][Full Text] [Related]
20. A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer.
Fakih MG; Pendyala L; Fetterly G; Toth K; Zwiebel JA; Espinoza-Delgado I; Litwin A; Rustum YM; Ross ME; Holleran JL; Egorin MJ
Clin Cancer Res; 2009 May; 15(9):3189-95. PubMed ID: 19383814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
